CD19-targeted CAR-T therapy

CD19-targeted CAR-T therapy is a revolutionary cancer treatment that involves modifying a patient’s own immune cells. These immune cells, called T cells, are taken from the patient and engineered in the laboratory to recognize a protein called CD19, found on the surface of many blood cancers, like certain leukemias and lymphomas. Once modified, these CAR-T cells are infused back into the patient, where they can specifically target and destroy the cancer cells expressing CD19. This personalized therapy has shown promising results, offering hope for patients with difficult-to-treat blood cancers.